MétaCan
Menu
Back to cohort

Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report

2020· article· en· W3043099150 on OpenAlexafffund
Zheng Zhou, Rajneesh Nath, Jan Černý, Hai-Lin Wang, Mei-Jie Zhang, Hisham Abdel‐Azim, Vaibhav Agrawal, Gulrayz Ahmed, A. Samer Al‐Homsi, Mahmoud Aljurf, Hassan B. Alkhateeb, Amer Assal, Ulrike Bacher, Ashish Bajel, Qaiser Bashir, Vijaya Raj Bhatt, Michael Byrne, Jean‐Yves Cahn, Mitchell S. Cairo, Hannah Choe, Edward A. Copelan, Corey Cutler, Moussab Damlaj, Zachariah DeFilipp, Marcos de Lima, Miguel Ángel Díaz, Nosha Farhadfar, James M. Foran, César O. Freytes, Aaron T. Gerds, Usama Gergis, Michael R. Grunwald, Zartash Gul, Mehdi Hamadani, Shahrukh K. Hashmi, Mark Hertzberg, Gerhard Hildebrandt, Nasheed Hossain, Yoshihiro Inamoto, Luis Isola, Tania Jain, Rammurti T. Kamble, Muhammad Khan, Mohamed A. Kharfan‐Dabaja, Partow Kebriaei, Natasha Kekre, Nandita Khera, Hillard M. Lazarus, Jane L. Liesveld, Mark R. Litzow, Hongtao Liu, David I. Marks, Rodrigo Martino, Vikram Mathews, Asmita Mishra, Hemant S. Murthy, Arnon Nagler, Ryotaro Nakamura, Sunita Nathan, Taiga Nishihori, Rebecca L. Olin, Richard F. Olsson, Neil Palmisiano, Sagar S. Patel, Mrinal M. Patnaik, Attaphol Pawarode, Miguel‐Angel Perales, Ioannis Politikos, Uday Popat, David A. Rizzieri, Brenda M. Sandmaier, Bipin N. Savani, Sachiko Seo, Nirav N. Shah, Geoffrey L. Uy, David Valcárcel, Leo F. Verdonck, Edmund K. Waller, Youjin Wang, Daniel J. Weisdorf, Baldeep Wirk, Eric Wong, Jean A. Yared, Wael Saber

Bibliographic record

VenueBlood Advances · 2020
Typearticle
Languageen
FieldMedicine
TopicHematopoietic Stem Cell Transplantation
Canadian institutionsOttawa Hospital
FundersMoonshot Research and Development ProgramNational Institute of Allergy and Infectious DiseasesOffice of Naval ResearchTakeda OncologyGenentechHealth Resources and Services AdministrationNational Institutes of HealthMacroGenicsOmeros CorporationJanssen Scientific AffairsMundipharma EDOAstellas PharmaAdaptive BiotechnologiesPfizerIncyteCTI Biopharmabluebird bioCancer MoonshotChimerixMedacJazz PharmaceuticalsJanssen BiotechHistoGeneticsNational Heart, Lung, and Blood InstituteNovartis Pharmaceuticals CorporationCelgeneKaryopharm TherapeuticsAtara BiotherapeuticsActinium PharmaceuticalsDaiichi Sankyo EuropeNational Cancer InstituteGilead SciencesBiomedical Advanced Research and Development AuthorityAmgenCSL BehringBristol-Myers SquibbJanssen PharmaceuticalsMemorial Sloan-Kettering Cancer CenterGlaxoSmithKlineAgios PharmaceuticalsSierra OncologyAstellas Pharma US
KeywordsMedicineBusulfanFludarabineMelphalanInternal medicineTotal body irradiationAlemtuzumabHazard ratioTransplantationMyeloid leukemiaGastroenterologySurgeryLeukemiaOncologyHematopoietic stem cell transplantationChemotherapyCyclophosphamideConfidence interval

Abstract

fetched live from OpenAlex

There is a lack of large comparative study on the outcomes of reduced intensity conditioning (RIC) in acute myeloid leukemia (AML) transplantation using fludarabine/busulfan (FB) and fludarabine/melphalan (FM) regimens. Adult AML patients from Center for International Blood and Marrow Transplant Research who received first RIC allo-transplant between 2001 and 2015 were studied. Patients were excluded if they received cord blood or identical twin transplant, total body irradiation in conditioning, or graft-versus-host disease (GVHD) prophylaxis with in vitro T-cell depletion. Primary outcome was overall survival (OS), secondary end points were leukemia-free survival (LFS), nonrelapse mortality (NRM), relapse, and GVHD. Multivariate survival model was used with adjustment for patient, leukemia, and transplant-related factors. A total of 622 patients received FM and 791 received FB RIC. Compared with FB, the FM group had fewer transplant in complete remission (CR), fewer matched sibling donors, and less usage of anti-thymocyte globulin or alemtuzumab. More patients in the FM group received marrow grafts and had transplantation before 2005. OS was significantly lower within the first 3 months posttransplant in the FM group (hazard ratio [HR] = 1.82, P < .001), but was marginally superior beyond 3 months (HR = 0.87, P = .05). LFS was better with FM compared with FB (HR = 0.89, P = .05). NRM was significantly increased in the FM group during the first 3 months of posttransplant (HR = 3.85, P < .001). Long-term relapse was lower with FM (HR = 0.65, P < .001). Analysis restricted to patients with CR showed comparable results. In conclusion, compared with FB, the FM RIC showed a marginally superior long-term OS and LFS and a lower relapse rate. A lower OS early posttransplant within 3 months was largely the result of a higher early NRM.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.019
Threshold uncertainty score0.879

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.034
GPT teacher head0.315
Teacher spread0.281 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations36
Published2020
Admission routes2
Has abstractyes

Explore more

Same venueBlood AdvancesSame topicHematopoietic Stem Cell TransplantationFrench-language works237,207